{"id":"W4396599757","doi":"10.1158/1538-7445.sabcs23-ps17-06","title":"Abstract PS17-06: A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"York University","funders":"","keywords":"Fulvestrant; Medicine; Estrogen receptor; Internal medicine; Estrogen; Oncology; Cancer; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008880202,0.001719699,0.001742326,0.0004890127,0.0004052611,0.001013387,0.0008229896,0.0008935013,0.00822453],"category_scores_gemma":[0.0006153376,0.0005841578,0.001302248,0.0005126235,0.001175775,0.001088552,0.0004129386,0.003995655,0.001758636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001273598,"about_ca_system_score_gemma":0.002379449,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001232913,"about_ca_topic_score_gemma":0.003056121,"domain_scores_codex":[0.999777,0.00008090851,0.00001480402,0.00004106791,0.00002314374,0.00006315184],"domain_scores_gemma":[0.9996112,0.00004115169,0.00004818145,0.00002018552,0.00001862485,0.0002607349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7586694,0.04446935,0.004815681,0.001430856,0.001539863,0.0004776446,0.000340118,0.003540383,0.0360375,0.0008142602,0.01072475,0.1371402],"study_design_scores_gemma":[0.6586525,0.3266537,0.005614117,0.0000517987,0.0003898866,0.0003630114,0.00006556942,0.0009553715,0.002687919,0.0003078194,0.004232356,0.00002591638],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856614,0.002561428,0.0005945835,0.0009752213,0.0002549963,0.003071238,0.002125295,0.000213916,0.004541836],"genre_scores_gemma":[0.9814642,0.002428613,0.001679789,0.001323623,0.0002608695,0.002986279,0.003862469,0.00004224269,0.005951864],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00822453,"threshold_uncertainty_score":0.02751374,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03390940358316925,"score_gpt":0.3827888557235882,"score_spread":0.3488794521404189,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}